Assessment of Cardiac Function, Microvascular Function and Cardiac Perfusion in Different Disease Stages of Hypertrophic Cardiomyopathy - Trial NCT06400524
Access comprehensive clinical trial information for NCT06400524 through Pure Global AI's free database. This phase not specified trial is sponsored by Amsterdam UMC, location VUmc and is currently Recruiting. The study focuses on Hypertrophic Cardiomyopathy,Hypertrophic Cardiomyopathy, Obstructive. Target enrollment is 100 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Amsterdam UMC, location VUmc
Timeline & Enrollment
N/A
May 01, 2024
May 01, 2026
Primary Outcome
myocardial blood flow,peripheral endothelial function
Summary
Hypertrophic cardiomyopathy (HCM) is a genetic disorder characterized by asymmetric
 hypertrophy of the heart in absence of loading conditions like hypertension. The genetic
 mutation underlying HCM sets in motion a cascade of functional and metabolic changes
 ultimately leading to disease. HCM patients often have microvascular dysfunction and
 myocardial perfusion deficits, of which the aetiology has not been elucidated. Whether these
 changes are secondary to remodelling or primarily caused by endothelial dysfunction is
 unclear. As the pathomechanism of HCM is thought to be a cascade of changes, it is important
 to gain more insight in the perfusion and endothelial function changes throughout different
 stages of disease: no phenotype, mild phenotype, and advanced HCM phenotype. In this study we
 aim to investigate these changes in the two most common genetic mutations.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06400524
Non-Device Trial